JP2006525360A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525360A5
JP2006525360A5 JP2006514221A JP2006514221A JP2006525360A5 JP 2006525360 A5 JP2006525360 A5 JP 2006525360A5 JP 2006514221 A JP2006514221 A JP 2006514221A JP 2006514221 A JP2006514221 A JP 2006514221A JP 2006525360 A5 JP2006525360 A5 JP 2006525360A5
Authority
JP
Japan
Prior art keywords
hmg
coa reductase
reductase inhibitor
ethylbutyl
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006514221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525360A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/013633 external-priority patent/WO2004098583A1/en
Publication of JP2006525360A publication Critical patent/JP2006525360A/ja
Publication of JP2006525360A5 publication Critical patent/JP2006525360A5/ja
Pending legal-status Critical Current

Links

JP2006514221A 2003-05-02 2004-04-30 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む併用 Pending JP2006525360A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46741803P 2003-05-02 2003-05-02
US47149503P 2003-05-16 2003-05-16
US47737203P 2003-06-10 2003-06-10
US53485604P 2004-01-08 2004-01-08
PCT/US2004/013633 WO2004098583A1 (en) 2003-05-02 2004-04-30 Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an hmg coa reductase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011284636A Division JP2012107018A (ja) 2003-05-02 2011-12-27 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む併用

Publications (2)

Publication Number Publication Date
JP2006525360A JP2006525360A (ja) 2006-11-09
JP2006525360A5 true JP2006525360A5 (cg-RX-API-DMAC7.html) 2007-05-10

Family

ID=33437189

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006514221A Pending JP2006525360A (ja) 2003-05-02 2004-04-30 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む併用
JP2011284636A Pending JP2012107018A (ja) 2003-05-02 2011-12-27 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011284636A Pending JP2012107018A (ja) 2003-05-02 2011-12-27 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む併用

Country Status (8)

Country Link
US (2) US20050020668A1 (cg-RX-API-DMAC7.html)
EP (3) EP1638545A1 (cg-RX-API-DMAC7.html)
JP (2) JP2006525360A (cg-RX-API-DMAC7.html)
CN (1) CN102512679A (cg-RX-API-DMAC7.html)
AR (1) AR044155A1 (cg-RX-API-DMAC7.html)
PE (1) PE20050148A1 (cg-RX-API-DMAC7.html)
TW (2) TWI393560B (cg-RX-API-DMAC7.html)
WO (1) WO2004098583A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
EP1603450A4 (en) 2003-03-07 2009-07-29 Univ Columbia PROCEDURE BASED ON TYPE 1 RYANODIN RECEPTOR
CA2519458A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
EP2287165A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2844245A1 (en) * 2012-04-30 2015-03-11 F. Hoffmann-La Roche AG New formulation
CN111073974B (zh) 2013-03-27 2024-04-09 豪夫迈·罗氏有限公司 用于预测对于治疗的响应性的遗传标记
JP6854752B2 (ja) 2014-07-30 2021-04-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー
WO2016112075A1 (en) 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
CN112601516A (zh) 2018-06-06 2021-04-02 艾尼纳制药公司 治疗与s1p1受体相关的病况的方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576830A (en) * 1966-08-12 1971-04-27 Sumitomo Chemical Co Amides containing sulfur
US4117158A (en) * 1977-09-27 1978-09-26 American Cyanamid Company 4-(monoalkylamino)benzonitriles useful as anti-atherosclerotic agents
US4177158A (en) * 1978-02-13 1979-12-04 Chevron Research Company Method for producing an attrition-resistant adsorbent for sulfur dioxide, the resulting composition and a process using same
US4346277A (en) * 1979-10-29 1982-08-24 Eaton Corporation Packaged electrical heating element
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
USRE36481E (en) * 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4740438A (en) * 1986-12-10 1988-04-26 Eastman Kodak Company Organic disulfides as image dye stabilizers
US4853319A (en) * 1986-12-22 1989-08-01 Eastman Kodak Company Photographic silver halide element and process
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5118583A (en) * 1988-10-12 1992-06-02 Mitsubishi Paper Mills Limited Processing composition for printing plate
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
FR2665450B1 (fr) * 1990-08-01 1994-04-08 Rhone Poulenc Chimie Procede de preparation de dispersions aqueuses de copolymeres.
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
WO1993011782A1 (en) * 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
US5519001A (en) * 1991-12-19 1996-05-21 Southwest Foundation For Biomedical Research CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
US5217859A (en) * 1992-04-16 1993-06-08 Eastman Kodak Company Aqueous, solid particle dispersions of dichalcogenides for photographic emulsions and coatings
US5219721A (en) * 1992-04-16 1993-06-15 Eastman Kodak Company Silver halide photographic emulsions sensitized in the presence of organic dichalcogenides
DK0680320T3 (da) * 1993-01-19 1999-10-25 Warner Lambert Co Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf
US5350667A (en) * 1993-06-17 1994-09-27 Eastman Kodak Company Photographic elements containing magenta couplers and process for using same
US5534529A (en) * 1993-06-30 1996-07-09 Sankyo Company, Limited Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
IL110159A0 (en) * 1993-06-30 1994-10-07 Wellcome Found Diaryl compounds, their preparation and pharmaceutical compositions containing them
US5446207A (en) * 1993-09-01 1995-08-29 Harbor Branch Oceanographic Institution, Inc. Anti-dyslipidemic agents
US5459154A (en) * 1993-11-08 1995-10-17 American Home Products Corporation N-hydroxyureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low density lipoprotein
US5405969A (en) * 1993-12-10 1995-04-11 Eastman Kodak Company Manufacture of thioether compounds
JP3304189B2 (ja) * 1994-03-18 2002-07-22 マツダ株式会社 加硫スクラップゴムを含有する成形用ゴム組成物及びその製造方法
US5654134A (en) * 1994-05-18 1997-08-05 Fuji Photo Film Co., Ltd. Silver halide emulsion
DE4428457C1 (de) * 1994-08-11 1995-10-05 Bayer Ag Geformte, paraffinhaltige Mastiziermittel
WO1996015141A1 (en) * 1994-11-12 1996-05-23 Lg Chemical Ltd. Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents
DE69520345T2 (de) * 1994-12-26 2001-09-06 Nisshin Flour Milling Co., Ltd. Diphenyl-disulfid Verbindungen
CN1087288C (zh) * 1995-07-17 2002-07-10 沃尼尔·朗伯公司 结晶[R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯氨基)羰基]－1H－吡咯－1－庚酸半钙盐
DE19610932A1 (de) * 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) * 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6462091B1 (en) * 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
DE19917233A1 (de) * 1999-04-16 2000-10-19 Aventis Pharma Gmbh Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids
US20010018446A1 (en) * 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6451830B1 (en) * 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
KR20030069983A (ko) * 2000-08-15 2003-08-27 화이자 프로덕츠 인코포레이티드 치료용 조합물
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CZ20033341A3 (cs) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
CA2519458A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
RU2006102981A (ru) * 2003-08-04 2007-09-20 Пфайзер Продактс Инк. (Us) Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы

Similar Documents

Publication Publication Date Title
JP2006525360A5 (cg-RX-API-DMAC7.html)
CN101217952B (zh) 用于预防心血管事件发病的组合物
JP2012107018A (ja) Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む併用
JP7716437B2 (ja) トリプレット組み合わせ製剤、及び心血管疾患を治療又はそのリスクを低下させる方法
JP2010155866A (ja) 高脂質血症および関連疾患の処置のための置換シアノピロリジンの使用およびそれらを含む組み合わせ製剤
JP2005532338A5 (cg-RX-API-DMAC7.html)
WO2001022962A1 (en) Anti-hypercholesterolemic drug combination
WO2001037831A1 (en) PHARMACEUTICAL COMBINATION COMPRISING SEPARATE DOSAGE FORMS IN A COMPLIANCE PACKAGE OF AN INHIBITOR OF HMG CoA REDUCTASE AND FIBRIC ACID DERIVATIVE
US20080272021A1 (en) Package for at Least Two Different Products to be Sold and Used Together
Mosca Optimal management of cholesterol levels and the prevention of coronary heart disease in women
JP2018027953A (ja) 膵炎を治療するためのゲムカベンおよび誘導体
TWI302457B (en) A pharmaceutical composition for improving blood lipid or reducing blood homocysteine
CN101193656B (zh) 甘油三酸酯降低剂
RU2007149337A (ru) Новый способ лечения гиперлипидемии
JP4880685B2 (ja) 薬物による不整脈の発生を低減するための組成物
Hanson et al. Drug eruption from atorvastatin: with initial misdiagnosis of tinea cruris
CN102341103A (zh) 贝特类的新用途
Ballantyne et al. 1084-176 Efficacy of ezetimibe coadministered with simvastatin versus atorvastatin in patients with hypercholesterolemia
ES2346969T3 (es) Uso de inhibidores de trombina de bajo peso molecular en terapia de disminucion de colesterol.
US20090280171A1 (en) Method of treatment with predictably breakable pharmaceutical tablets
CN119546300A (zh) 血中ldl胆固醇降低剂
Blom et al. New therapeutic developments in lipidology
Elliott et al. Pharmacology Update: Omega-3-Acid Ethyl Esters Capsules (Omacor)
Parmar Courting hyperlipidemia
Mann Rosuvastatin